



**Research & Development
Claim Support Document
Hygiene, Personal Care**

HEALTH ▸ HYGIENE ▸ HOME

*Attorney-Client Privileged Document
Not to be Copied, Forwarded, or Quoted From
Without Permission of Originator*

	Stage: Final
Document UDN #	M5028-039-v1.0
Product Name/ Description	Dettol 2 in 1 Antibacterial Wipes
Product Formula Code Tested	TDS 8298426, Lot # EW25102019005
Bridging To	8291228
Dilution & Contact time	Neat, 2 min contact time

Claims

Claim	Claim Substantiated
1. NOW TESTED AND PROVEN EFFECTIVE TO KILL COVID-19 VIRUS / SARS-CoV-2	YES
2. NOW TESTED AND PROVEN EFFECTIVE AGAINST THE COVID-19 VIRUS	YES

Objective

To provide a claims memo on the effectiveness against SARS-CoV-2 (COVID-19) strain and to provide bridging guidance across other TDS codes.

Success Criteria

>= 4.0 log reduction against SARS-CoV-2

Test Methods

EN14476:2013+A2:2019. Product tested neat at a 2 min contact time.

Per the scope of this method: "This European Standard applies to products that are used in the medical area in the fields of hygienic handrub, hygienic handwash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding or other means and textile disinfection."

Results and Conclusion

The Product Dettol 2 in 1 Antibacterial Wipes TDS 8298426, when tested according to EN14476:2013+A2:2019 method, passes with a ≥ 4.18 log reduction at a contact time of 2 minutes and



**Research & Development
Claim Support Document
Hygiene, Personal Care**

HEALTH ▸ HYGIENE ▸ HOME

***Attorney-Client Privileged Document
Not to be Copied, Forwarded, or Quoted From
Without Permission of Originator***

when tested under dirty conditions at 20°C -21°C. All controls met the required method criteria and there were no deviations which impacted the results of this study.

The product has been shown to be effective in inactivating / killing SARS-CoV-2 (COVID-19) strain which causes COVID illness.

The final SARS CoV-2 Report for this listed testing can be found contained with UDN # M5028-011-v1.0

Formulation & Bridging

Dettol 2 in 1 Antibacterial Wipes TDS 8298426 lot # EW25102019005 was tested against the SARS-CoV-2 (COVID-19) strain. The product was tested neat, at 2 min contact time.

Category R&D and Micro R&D performed a formula comparison against all global formulations. Formula comparison is attached in Appendix 1. Based on the formula similarities and below rationale, the data generated on Dettol 2 in 1 Antibacterial Wipes TDS 8298426 can be bridged to the TDS codes listed under the "Bridging to" section.






1. All formulations contain the same active ingredient benzalkonium chloride (BKC) as the tested formula
2. All formulations contain the same concentration of the active benzalkonium chloride as the tested formula
3. All formulas have the same pH specification
4. The only difference in the formulation is the fragrance which is not expected to have any impact on the virucidal efficacy
5. Loading ratio of the liquid to the wipe is same as the tested formula



**Research & Development
Claim Support Document
Hygiene, Personal Care**

HEALTH ▸ HYGIENE ▸ HOME

**Attorney-Client Privileged Document
Not to be Copied, Forwarded, or Quoted From
Without Permission of Originator**

Approvals	Signature	Date
Kelly Whitehead Sr. Associate Microbiology R&D	DocuSigned by: Kelly Whitehead  Signer Name: Kelly Whitehead Signing Reason: I approve this document Signing Time: 04-06-2020 13:40 BST 3403A88098DB46E68C57881234A17E00	04-06-2020 13:41 BST
Vanita Srinivasan Sr. Manager Microbiology R&D	DocuSigned by: Vanita Srinivasan  Signer Name: Vanita Srinivasan Signing Reason: I approve this document Signing Time: 04-06-2020 13:22 BST 107A80F84F3D49A483A919B9647E2E69	04-06-2020 13:23 BST
Julie Mckinney Director ECC	DocuSigned by: Julie McKinney  Signer Name: Julie McKinney Signing Reason: I approve this document Signing Time: 05-06-2020 06:43 PDT 9815C201896E43E7BD6CF9E58BE63AF7	05-06-2020 06:43 PDT
Krzysztof Paziewski Sr. Manager Dettol R&D	DocuSigned by: Paziewski, Krzysztof  Signer Name: Paziewski, Krzysztof Signing Reason: I approve this document Signing Time: 04-06-2020 14:51 BST ACF7566A137B476DB698427A28FB2263	04-06-2020 14:51 BST
Mark Ripley CGD Health Hygiene R&D	DocuSigned by: Ripley, Mark  Signer Name: Ripley, Mark Signing Reason: I approve this document Signing Time: 04-06-2020 05:28 PDT F38FF1FB739A41449ED3B6F44DB9CC57	04-06-2020 05:28 PDT



HEALTH ▸ HYGIENE ▸ HOME

**Research & Development
Claim Support Document
Hygiene, Personal Care**

*Attorney-Client Privileged Document
Not to be Copied, Forwarded, or Quoted From
Without Permission of Originator*

Appendix 1

Formula comparison

	TESTED FORMULA	BRIDGED FORMULA
Loading Ratio	2.42:1	2.42:1
FF TDS # (Concentrate + Substrate)	8298426	8291228
Concentrate TDS #	8298427	8291235
Active -Benzalkonium Chloride	0.47% - 0.57%	0.47% - 0.57%
pH	4.5-8.5	4.5 - 8.5
SUBSTRATES		
NON WOVEN VIS 65% / PES 35% (65% Viscose, 35% Polyester)	29.24	30.24
INGREDIENTS	(%w/w)	(%w/w)
DEIONISED WATER EUROPE	95.91	95.91
BENZALKONIUM CHLORIDE 50% (CAS 68424-85-1)	1.04	1.04
ETHANOL 96° BITREX	3.00	3.00
CITRON GIVRE MINT G111 11796	0.05	
181316F YUCATAN		0.05
	100	100

Certificate Of Completion

Envelope Id: 50501687557145BA9F608F8132100ABD	Status: Completed
Subject: Please DocuSign: Dettol 2-in1 Wipes.doc	
Source Envelope:	
Document Pages: 4	Signatures: 5
Certificate Pages: 6	Initials: 0
AutoNav: Enabled	Envelope Originator:
Envelopeld Stamping: Enabled	Vanita Srinivasan
Time Zone: (UTC) Dublin, Edinburgh, Lisbon, London	103-105 Bath Rd.
	Slough, uk SL1 3UH
	Vanita.Srinivasan@rb.com
	IP Address: 74.102.218.225

Record Tracking

Status: Original Jun 4, 2020 13:04	Holder: Vanita Srinivasan Vanita.Srinivasan@rb.com	Location: DocuSign
---	---	--------------------

Signer Events

Signer Events	Signature	Timestamp
Julie McKinney Julie.McKinney@rb.com Director, Equity, Claims and Compliance Julie McKinney Security Level: Email, Account Authentication (Required)	Julie McKinney Signature Adoption: Pre-selected Style Signature ID: 9815C201-896E-43E7-BD6C-F9E58BE63AF7 Using IP Address: 174.226.18.254 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: Jun 4, 2020 13:21 Viewed: Jun 5, 2020 14:43 Signed: Jun 5, 2020 14:43

Electronic Record and Signature Disclosure:
Accepted: Apr 22, 2020 | 18:30
ID: 6e7ba292-f52c-47e5-b427-b1cfa690af1d

Kelly Whitehead Kelly.Whitehead@rb.com R and D Senior Associate RB-GxP Security Level: Email, Account Authentication (Required)	Kelly Whitehead Signature Adoption: Pre-selected Style Signature ID: 3403A880-98DB-46E6-8C57-881234A17E00 Using IP Address: 70.44.49.212 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: Jun 4, 2020 13:21 Viewed: Jun 4, 2020 13:39 Signed: Jun 4, 2020 13:41
---	--	---

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

Signer Events	Signature	Timestamp
<p>Paziewski, Krzysztof Krzysztof.Paziewski@rb.com Reckitt Benckiser Corporate Services Limited Security Level: Email, Account Authentication (Required)</p> <p>Electronic Record and Signature Disclosure: Accepted: Nov 3, 2017 15:17 ID: 953cac4d-dd51-49ae-9631-cac774b45daf</p>	<p>Paziewski, Krzysztof</p> <p>Signature Adoption: Pre-selected Style Signature ID: ACF7566A-137B-476D-B698-427A28FB2263 Using IP Address: 68.196.25.197</p> <p>With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document</p>	<p>Sent: Jun 4, 2020 13:21 Viewed: Jun 4, 2020 14:49 Signed: Jun 4, 2020 14:51</p>
<p>Ripley, Mark Mark.Ripley@rb.com Mark Ripley Security Level: Email, Account Authentication (Required)</p> <p>Electronic Record and Signature Disclosure: Accepted: Aug 27, 2019 17:18 ID: 828011f2-2187-4d58-be43-b47f7b71ed1f</p>	<p>Ripley, Mark</p> <p>Signature Adoption: Pre-selected Style Signature ID: F38FF1FB-739A-4144-9ED3-B6F44DB9CC57 Using IP Address: 12.187.100.162</p> <p>With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document</p>	<p>Sent: Jun 4, 2020 13:21 Viewed: Jun 4, 2020 13:28 Signed: Jun 4, 2020 13:28</p>
<p>Vanita Srinivasan vanita.srinivasan@rb.com R and D Manager RB-GxP Security Level: Email, Account Authentication (Required)</p> <p>Electronic Record and Signature Disclosure: Not Offered via DocuSign</p>	<p><i>Vanita Srinivasan</i></p> <p>Signature Adoption: Pre-selected Style Signature ID: 107A80F8-4F3D-49A4-83A9-19B9647E2E69 Using IP Address: 74.102.218.225</p> <p>With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document</p>	<p>Sent: Jun 4, 2020 13:21 Viewed: Jun 4, 2020 13:22 Signed: Jun 4, 2020 13:23</p>
In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp

Witness Events	Signature	Timestamp
-----------------------	------------------	------------------

Notary Events	Signature	Timestamp
----------------------	------------------	------------------

Envelope Summary Events	Status	Timestamps
--------------------------------	---------------	-------------------

Envelope Sent	Hashed/Encrypted	Jun 4, 2020 13:21
Certified Delivered	Security Checked	Jun 5, 2020 14:43
Signing Complete	Security Checked	Jun 5, 2020 14:43
Completed	Security Checked	Jun 5, 2020 14:43

Payment Events	Status	Timestamps
-----------------------	---------------	-------------------

Electronic Record and Signature Disclosure

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, RB-GxP (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through your DocuSign, Inc. (DocuSign) Express user account. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your agreement by clicking the 'I agree' button at the bottom of this document.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. For such copies, as long as you are an authorized user of the DocuSign system you will have the ability to download and print any documents we send to you through your DocuSign user account for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of your DocuSign account. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use your DocuSign Express user account to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through your DocuSign user account all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact RB-GxP:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: niran.perera@rb.com

To advise RB-GxP of your new e-mail address

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at niran.perera@rb.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address..

In addition, you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in DocuSign.

To request paper copies from RB-GxP

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an e-mail to niran.perera@rb.com and in the body of such request you must state your e-mail address, full name, US Postal address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with RB-GxP

To inform us that you no longer want to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your DocuSign account, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an e-mail to niran.perera@rb.com and in the body of such request you must state your e-mail, full name, IS Postal Address, telephone number, and account number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

Operating Systems:	Windows2000? or WindowsXP?
Browsers (for SENDERS):	Internet Explorer 6.0? or above
Browsers (for SIGNERS):	Internet Explorer 6.0?, Mozilla FireFox 1.0, NetScape 7.2 (or above)
Email:	Access to a valid email account
Screen Resolution:	800 x 600 minimum
Enabled Security Settings:	<ul style="list-style-type: none"> •Allow per session cookies •Users accessing the internet behind a Proxy Server must enable HTTP 1.1 settings via proxy connection

** These minimum requirements are subject to change. If these requirements change, we will provide you with an email message at the email address we have on file for you at that time providing you with the revised hardware and software requirements, at which time you will have the right to withdraw your consent.

Acknowledging your access and consent to receive materials electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to e-mail this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.

By checking the 'I Agree' box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC RECORD AND SIGNATURE DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I notify RB-GxP as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by RB-GxP during the course of my relationship with you.